Assignee
GENMAB AS
DK·79 granted patents·148 pending applications·1,292 citations·filing 2002–2025
Top patents by PatentIndex Score
227 records- 0198US11485796B2Inert formatGENMAB AS·Filed 2020·Granted Nov 1, 2022·6 cites·20 claims
- 0298US11440966B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 13, 2022·12 cites·21 claims
- 0398US11084882B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2020·Granted Aug 10, 2021·8 cites·11 claims
- 0498US7829673B2Antibodies against CD38 for treatment of multiple myelomaGENMAB AS·Filed 2006·Granted Nov 9, 2010·148 cites·29 claims
- 0598US7247301B2Human monoclonal antibodies to epidermal growth factor receptor (EGFR)GENMAB AS·Filed 2002·Granted Jul 24, 2007·215 cites·24 claims
- 0698US7153507B2Human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2002·Granted Dec 26, 2006·367 cites·32 claims
- 0797US11866514B2Heterodimeric antibody Fc-containing proteins and methods for production thereofGENMAB AS·Filed 2020·Granted Jan 9, 2024·5 cites·37 claims
- 0897US10597464B2Heterodimeric antibody Fc-containing proteins and methods for production thereofGENMAB AS·Filed 2017·Granted Mar 24, 2020·35 cites·12 claims
- 0996US11608383B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Mar 21, 2023·8 cites·30 claims
- 1096US11535679B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Dec 27, 2022·8 cites·27 claims
- 1196US11091557B2Methods of producing multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2017·Granted Aug 17, 2021·10 cites·20 claims
- 1296US10590206B2Inert formatGENMAB AS·Filed 2014·Granted Mar 17, 2020·29 cites·20 claims
- 1395US12077596B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 3, 2024·2 cites·20 claims
- 1495US11939388B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Mar 26, 2024·2 cites·13 claims
- 1595US11845805B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Dec 19, 2023·5 cites·33 claims
- 1695US11548952B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Jan 10, 2023·7 cites·27 claims
- 1795US10906991B2Bispecific antibodies and methods for production thereofGENMAB AS·Filed 2015·Granted Feb 2, 2021·15 cites·6 claims
- 1895US10344050B2Production of heterodimeric proteinsGENMAB AS·Filed 2012·Granted Jul 9, 2019·40 cites·52 claims
- 1994US10407501B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2015·Granted Sep 10, 2019·15 cites·19 claims
- 2094US7595378B2Human monoclonal antibodies to epidermal growth factor receptor (EGFR)GENMAB AS·Filed 2002·Granted Sep 29, 2009·64 cites·14 claims
- 2194US7438907B2Human monoclonal antibodies against CD25GENMAB AS·Filed 2003·Granted Oct 21, 2008·50 cites·31 claims
- 2293US11858995B2Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Granted Jan 2, 2024·4 cites·28 claims
- 2393US11492371B2Production of heterodimeric proteinsGENMAB AS·Filed 2019·Granted Nov 8, 2022·9 cites·21 claims
- 2493US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 2593US9944711B2Antibodies against human CD38GENMAB AS·Filed 2016·Granted Apr 17, 2018·16 cites·48 claims
- 2693US9492565B2Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2015·Granted Nov 15, 2016·7 cites·16 claims
- 2793US7282568B2Human monoclonal antibodies against interleukin 8 (IL-8)GENMAB AS·Filed 2003·Granted Oct 16, 2007·39 cites·23 claims
- 2892US11613575B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2019·Granted Mar 28, 2023·4 cites·18 claims
- 2992US11359015B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2016·Granted Jun 14, 2022·6 cites·24 claims
- 3092US9657107B2Monoclonal antibodies against c-MetGENMAB AS·Filed 2015·Granted May 23, 2017·9 cites·25 claims
- 3191US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 3291US7850962B2Human monoclonal antibodies against CD20GENMAB AS·Filed 2005·Granted Dec 14, 2010·27 cites·49 claims
- 3390US10201607B2Antibodies binding AXLGENMAB AS·Filed 2018·Granted Feb 12, 2019·7 cites·28 claims
- 3490US9714297B2Human antibodies against tissue factor and methods of use thereofGENMAB AS·Filed 2015·Granted Jul 25, 2017·9 cites·29 claims
- 3589US10765743B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Sep 8, 2020·3 cites·46 claims
- 3688US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 3788US7622559B2Human monoclonal antibodies against interleukin 8 (IL-8)GENMAB AS·Filed 2007·Granted Nov 24, 2009·7 cites·15 claims
- 3887US10500276B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Dec 10, 2019·4 cites·35 claims
- 3986US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 4086US10512688B2Antibodies binding AXLGENMAB AS·Filed 2015·Granted Dec 24, 2019·4 cites·8 claims
- 4186US2024294661A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2023·Application pending·0 cites
- 4286US2024209117A1Heterodimeric antibody fc-containing proteins and methods for production thereofGENMAB AS·Filed 2023·Application pending·0 cites
- 4385US11046771B2Monoclonal antibodies against HER2GENMAB AS·Filed 2017·Granted Jun 29, 2021·2 cites·23 claims
- 4485US7329405B2Human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2003·Granted Feb 12, 2008·11 cites·10 claims
- 4585US7247304B2Methods of treating using anti-IL-15 antibodiesGENMAB AS·Filed 2003·Granted Jul 24, 2007·21 cites·18 claims
- 4685US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 4784US12589150B2Antibodies binding AXLGENMAB AS·Filed 2023·Granted Mar 31, 2026·0 cites·21 claims
- 4884US9598493B2Human monoclonal antibodies against CD25GENMAB AS·Filed 2015·Granted Mar 21, 2017·3 cites·11 claims
- 4984US7585961B2Nucleic acid encoding human antibodies specific for interleukin 15 (IL-15)GENMAB AS·Filed 2007·Granted Sep 8, 2009·5 cites·22 claims
- 5084US2024228662A9Antibodies against cd38 for treatment of multiple myelomaGENMAB AS·Filed 2023·Application pending·0 cites
Showing the top 50 of 227 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when GENMAB AS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →